

**RIPK2 Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13758a**

**Specification**

**RIPK2 Antibody (N-term) Blocking peptide - Product Information**

Primary Accession [O43353](#)

**RIPK2 Antibody (N-term) Blocking peptide - Additional Information**

**Gene ID** 8767

**Other Names**

Receptor-interacting serine/threonine-protein kinase 2, CARD-containing interleukin-1 beta-converting enzyme-associated kinase, CARD-containing IL-1 beta ICE-kinase, RIP-like-interacting CLARP kinase, Receptor-interacting protein 2, RIP-2, Tyrosine-protein kinase RIPK2, RIPK2, CARDIAK, RICK, RIP2

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13758a was selected from the N-term region of RIPK2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**RIPK2 Antibody (N-term) Blocking peptide - Protein Information**

**Name** RIPK2 {ECO:0000303|PubMed:30026309, ECO:0000312|HGNC:HGNC:10020}

**Function**

Serine/threonine/tyrosine-protein kinase that plays an essential role in modulation of innate and adaptive immune responses (PubMed:<a href="http://www.uniprot.org/citations/9575181" target="\_blank">9575181</a>, PubMed:<a href="http://www.uniprot.org/citations/9642260" target="\_blank">9642260</a>, PubMed:<a href="http://www.uniprot.org/citations/14638696" target="\_blank">14638696</a>, PubMed:<a href="http://www.uniprot.org/citations/21123652" target="\_blank">21123652</a>, PubMed:<a href="http://www.uniprot.org/citations/17054981" target="\_blank">17054981</a>, PubMed:<a href="http://www.uniprot.org/citations/28656966" target="\_blank">28656966</a>). Acts as a key effector of NOD1 and NOD2 signaling pathways: upon activation by bacterial peptidoglycans, NOD1 and NOD2 oligomerize and recruit RIPK2 via CARD-CARD domains, leading to the formation of RIPK2 filaments (PubMed:<a

Once recruited, RIPK2 autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3, as well as 'Met-1'-linked (linear) polyubiquitination by the LUBAC complex, becoming a scaffolding protein for downstream effectors (PubMed:<a href="http://www.uniprot.org/citations/22607974" target="\_blank">22607974</a>, PubMed:<a href="http://www.uniprot.org/citations/29452636" target="\_blank">29452636</a>, PubMed:<a href="http://www.uniprot.org/citations/30026309" target="\_blank">30026309</a>). Once 'Met-1'-linked polyubiquitin chains attached to RIPK2 recruit IKBKG/NEMO, which undergoes 'Lys-63'-linked polyubiquitination in a RIPK2-dependent process (PubMed:<a href="http://www.uniprot.org/citations/22607974" target="\_blank">22607974</a>, PubMed:<a href="http://www.uniprot.org/citations/17562858" target="\_blank">17562858</a>, PubMed:<a href="http://www.uniprot.org/citations/29452636" target="\_blank">29452636</a>, PubMed:<a href="http://www.uniprot.org/citations/30026309" target="\_blank">30026309</a>). 'Lys-63'-linked polyubiquitin chains attached to RIPK2 serve as docking sites for TAB2 and TAB3 and mediate the recruitment of MAP3K7/TAK1 to IKBKG/NEMO, inducing subsequent activation of IKBKB/IKKB (PubMed:<a href="http://www.uniprot.org/citations/18079694" target="\_blank">18079694</a>). In turn, NF-kappa-B is released from NF-kappa-B inhibitors and translocates into the nucleus where it activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis (PubMed:<a href="http://www.uniprot.org/citations/18079694" target="\_blank">18079694</a>). The protein kinase activity is dispensable for the NOD1 and NOD2 signaling pathways (PubMed:<a href="http://www.uniprot.org/citations/29452636" target="\_blank">29452636</a>, PubMed:<a href="http://www.uniprot.org/citations/30026309" target="\_blank">30026309</a>). Contributes to the tyrosine phosphorylation of the guanine exchange factor ARHGEF2 through Src tyrosine kinase leading to NF-kappa-B activation by NOD2 (PubMed:<a href="http://www.uniprot.org/citations/21887730" target="\_blank">21887730</a>). Also involved in adaptive immunity: plays a role during engagement of the T-cell receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-kappa-B activation (PubMed:<a href="http://www.uniprot.org/citations/14638696" target="\_blank">14638696</a>). Plays a role in the inactivation of RHOA in response to NGFR signaling (PubMed:<a href="http://www.uniprot.org/citations/26646181" target="\_blank">26646181</a>).

### Cellular Location

Cytoplasm. Cell membrane; Peripheral membrane protein. Endoplasmic reticulum. Note=Recruited to the cell membrane by NOD2 following stimulation by bacterial peptidoglycans

### Tissue Location

Detected in heart, brain, placenta, lung, peripheral blood leukocytes, spleen, kidney, testis, prostate, pancreas and lymph node.

### RIPK2 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### RIPK2 Antibody (N-term) Blocking peptide - Images

### RIPK2 Antibody (N-term) Blocking peptide - Background

This gene encodes a member of the receptor-interactingprotein (RIP) family of serine/threonine protein kinases. Theencoded protein contains a C-terminal caspase activation andrecruitment domain (CARD), and is a component of signalingcomplexes in both the innate and adaptive immune pathways. It is a potent activator of NF-kappaB and inducer of apoptosis in responseto various stimuli.

### RIPK2 Antibody (N-term) Blocking peptide - References

Cirulli, E.T., et al. Eur. J. Hum. Genet. 18(7):815-820(2010)  
Du, X., et al. Mol. Cell. Biochem. 337 (1-2), 277-285 (2010) :  
Adams, S., et al. Exp. Cell Res. 316(5):728-736(2010)  
Zhang, F.R., et al. N. Engl. J. Med. 361(27):2609-2618(2009)  
Hosgood, H.D. III, et al. Occup Environ Med 66(12):848-853(2009)